Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics statnews.com
- Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback scmp.com
- FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting endpoints.news
- FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector ft.com
- FDA declines approval of Summit’s lung cancer treatment seekingalpha.com